Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Hospira

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Trial of Amgen, Servier’s heart failure drug clears interim check

Drug could become a $2bn product if approved

- PMLiVE

Can protein degraders unlock ‘undruggable’ drug targets?

Exploring a new and exciting area of small-molecule drug discovery

- PMLiVE

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

EU approval will help drug achieve blockbuster status

- PMLiVE

Ex-Sandoz exec admits role in generic drug price-fixing plot

Reignites criticism of high drug prices in the US

Novartis day

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

New drug due for launch in Europe in the second quarter

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

Novartis plans inclisiran trial in the UK

Swiss pharma also officially opens new London headquarters

Novartis day

Novartis pulls ahead of Merck in MET-positive lung cancer race

FDA starts priority review of Swiss pharma's MET inhibitor

- PMLiVE

Biogen triumphs over Mylan’s Tecfidera patent challenge

Shares in Biogen skyrocketed by 32% following ruling

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

- PMLiVE

Novartis faces criticism over Zolgensma ‘health lottery’

SMA Europe deems access programme 'inappropriate'

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links